Physician profile
Andreea Nagy
NPI 1376171496
$2,126.64
in general payments reported to CMS, 2019-2025
28 companies · $656 in 2025
The $656 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $259 · 2023: $436 · 2024: $625 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.14 | 2021-2025 | |
| Glaxosmithkline, LLC. | $290.16 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $276.04 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $184.35 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $127.77 | 2024-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $102.96 | 2023-2024 | |
| Pfizer INC. | $81.22 | 2022-2024 | |
| Exact Sciences Corporation | $67.79 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.33 | 2023-2025 | Xifaxan |
| Abiomed | $32.99 | 2023 | Impella |
| Novartis Pharmaceuticals Corporation | $30.55 | 2022-2025 | |
| Boston Scientific Corporation | $29.06 | 2025 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $26.75 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.59 | 2022 | |
| Globus Medical, INC. | $25.83 | 2025 | Senza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $24.53 | 2025 | |
| Amarin Pharma, INC. | $22.92 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.02 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $20.64 | 2021 | |
| Radius Health, INC. | $19.72 | 2024 | Tymlos |
| Astellas Pharma US INC | $18.88 | 2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $18.44 | 2024 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $17.57 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $13.79 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $13.21 | 2024 | Nuzyra |
| Shield Therapeutics INC | $13.15 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $12.27 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreea Nagy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.